Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733564 | 1.00 | ABL1 (0.51) | ABL1OPRK1GAATSHRALDH1A1 | |
| SCHEMBL473981 | 0.82 | OPRK1 (0.48) | ABL1OPRK1GAATSHRALDH1A1 | |
| SCHEMBL27779499 | 0.82 | OPRK1 (0.48) | ABL1OPRK1GAATSHRALDH1A1 | |
| SCHEMBL30816026 | 0.82 | OPRK1 (0.48) | ABL1OPRK1GAATSHRALDH1A1 | |
| SCHEMBL4413388 | 0.82 | CHEK2 (0.56) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL17382217 | 0.81 | ATM (0.47) | ABL1OPRK1GAATSHRALDH1A1 | |
| SCHEMBL401530 | 0.81 | OPRK1 (0.47) | ABL1OPRK1GAAALDH1A1KDM4E | |
| SCHEMBL27818191 | 0.81 | KDM4E (0.50) | ABL1GAATSHRALDH1A1KDM4E | |
| SCHEMBL4869343 | 0.80 | SCN9A (0.39) | KDM4EMAPTHPGDIKBKETBK1 | |
| SCHEMBL31382687 | 0.80 | SCN9A (0.39) | KDM4EMAPTHPGDIKBKETBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515685-B | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023067546-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2006088920-A1 | AMINE-LINKED PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006088840-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2006-08-24 | — | — | WO | disclosed |
| US-5604239-A | GASTROINTESTINAL AND PSYCHOLOGICAL DISORDERS | G. D. SEARLE & CO. (US) | 1997-02-18 | — | — | US | disclosed |
| US-5591749-A | ANXIOLYTIC AND ANTIDEPRESSANT AGENTS; GASTROINTESTINAL AND PSYCHOLOGICAL DISORDERS | G. D. SEARLE & CO. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5434161-A | FOR TREATING ANXIETY, PSYCHOSES, DEPRESSION OR GASTROINTESTINAL MOTILITY | G. D. SEARLE & CO. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0568540-A1 | 2,4-DIOXO-PYRIDO 2,3-d]PYRIMIDINE-3-ACETIC ACIDS AND ESTERS AND SALTS THEREOF | PFIZER INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| EP-0530353-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT 3? ANTAGONISTS | G.D. SEARLE & CO. (US) | 1993-03-10 | — | — | EP | disclosed |
| EP-0504679-A1 | New imidazopyridines as serotonergic 5-HT3 antagonists | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992015593-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT3 ANTAGONISTS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | disclosed |
| WO-1992012979-A1 | 2,4-DIOXO-PYRIDO [2,3-d]PYRIMIDINE-3-ACETIC ACIDS AND ESTERS AND SALTS THEREOF | PFIZER INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | ABL1 888/4885OPRK1 3949/4885GAA 2552/4885 |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | KRAS, NRAS, SOS1 | ABL1 232/4885OPRK1 2664/4885GAA 3552/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ABL1 888/4885OPRK1 3949/4885GAA 2552/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ABL1 888/4885OPRK1 3949/4885GAA 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.